Wu Xiaoxia et al. presented a series of six MPAL patients (five: B-cell/myeloid MPAL, one: B-cell/T-cell MPA, three: KMT2A abnormalities, and one: BCR: ABL1 abnormalities), who were all given blinatumomab and venetoclax as induction therapy and, except two, achieved complete remission, as measured by MRD [108]. This evidence concerns the gene ABL1 and mixed phenotype acute leukemia.